Cargando…
A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
BACKGROUND: Inflammatory cytokine markers, including the neutrophil-to-lymphocyte ratio (NLR), monocyte-lymphocyte ratio, and platelet-to-lymphocyte ratio, play important roles as prognostic markers in several solid malignancies, including prostate cancer. We previously reported the NLR as a poor pr...
Autores principales: | Kawahara, Takashi, Kato, Masashi, Tabata, Kenichi, Kojima, Ippei, Yamada, Hiroshi, Kamihira, Osamu, Tsumura, Hideyasu, Iwamura, Masatsugu, Uemura, Hiroji, Miyoshi, Yasuhide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519532/ https://www.ncbi.nlm.nih.gov/pubmed/32977754 http://dx.doi.org/10.1186/s12885-020-07410-2 |
Ejemplares similares
-
Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
por: Kawahara, Takashi, et al.
Publicado: (2023) -
Prognosis and safety of radium‐223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration‐resistant prostate cancer: Real‐world data of Japanese patients
por: Miyoshi, Yasuhide, et al.
Publicado: (2020) -
Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis
por: Yamada, Yoko, et al.
Publicado: (2016) -
Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide
por: Kumano, Yohei, et al.
Publicado: (2019) -
Changing the Timing of Enzalutamide Intake from Morning to before Sleep at Night Overcame Enzalutamide-Induced Dysgeusia
por: Kawahara, Takashi, et al.
Publicado: (2019)